​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

GMAB Stock Forecast

Genmab (GMAB) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $50.60, with a high of $70.00 and a low of $40.00. This represents a -10.43% decline from the last price of $56.49.

$25 $34 $43 $52 $61 $70 High: $70 Avg: $50.6 Low: $40 Last Closed Price: $56.49

GMAB Stock Rating

Genmab stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (77.78%), 3 Hold (16.67%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 3 14 0 Strong Sell Sell Hold Buy Strong Buy

GMAB Price Target Upside V Benchmarks

TypeNameUpside
StockGenmab-10.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4412
Avg Price Target$56.00$56.00$45.46
Last Closing Price$56.49$56.49$56.49
Upside/Downside-0.87%-0.87%-19.53%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26191--11
Sep, 261101--12
Aug, 26-101--11
Jul, 26-92--11
Jun, 26-92--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2026H.C. Wainwright$70.00$57.2922.19%23.92%
Oct 20, 2026Sean LaamanMorgan Stanley$42.00$38.509.09%-25.65%
Oct 07, 2026Michael SchmidtGuggenheim$58.00$37.8053.44%2.67%
Oct 05, 2026Michael SchmidtGuggenheim$54.00$34.7555.40%-4.41%
Jul 22, 2026New Street$43.00$28.3751.57%-23.88%
May 27, 2026Gregory RenzaTruist Financial$40.00$26.8948.75%-29.19%
Apr 30, 2026H.C. Wainwright$38.00$26.1145.54%-32.73%
Mar 26, 2026Wolfe Research$32.00$26.0322.94%-43.35%
Feb 23, 2026Michael SchmidtGuggenheim$40.00$29.2936.57%-29.19%
Feb 17, 2026Benjamin JacksonJefferies$41.50$30.0338.20%-26.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2026H.C. WainwrightBuyBuyhold
Oct 26, 2026Cowen & Co.BuyBuyhold
Oct 07, 2026H.C. WainwrightBuyBuyhold
Oct 05, 2026GuggenheimBuyBuyhold
Sep 14, 2026H.C. WainwrightBuyBuyhold
Sep 01, 2026Deutsche BankBuyBuyhold
Jul 22, 2026Cowen & Co.HoldBuyupgrade
Jul 02, 2026H.C. WainwrightBuyBuyhold
May 11, 2026Deutsche BankBuyBuyhold
Mar 26, 2026Wolfe ResearchOutperforminitialise

Financial Forecast

EPS Forecast

$0 $14 $28 $42 $56 $70 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.60$8.45$66.64-----
Avg Forecast$4.37$9.88$7.48$8.66$9.62$12.41$17.92$22.36
High Forecast$4.60$10.45$8.36$9.91$14.02$14.13$20.13$23.89
Low Forecast$4.06$8.83$6.85$7.76$7.48$8.31$15.91$19.63
Surprise %5.26%-14.47%790.91%-----

Revenue Forecast

$5B $13B $21B $29B $37B $45B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.48B$14.60B$16.47B-----
Avg Forecast$8.39B$14.05B$16.16B$21.64B$25.39B$29.23B$33.61B$39.61B
High Forecast$8.74B$14.68B$16.44B$22.57B$26.31B$29.40B$33.81B$41.70B
Low Forecast$7.94B$12.91B$15.89B$20.78B$24.04B$29.06B$33.41B$35.89B
Surprise %1.10%3.89%1.92%-----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.96B$5.45B$4.35B-----
Avg Forecast$15.19B$14.90B$4.35B$582.45M$708.62M$739.70M$1.19B$1.47B
High Forecast$18.22B$17.88B$5.22B$653.26M$924.29M$931.50M$1.33B$1.57B
Low Forecast$12.15B$11.92B$3.48B$511.65M$492.95M$547.90M$1.05B$1.29B
Surprise %-80.53%-63.41%------

GMAB Forecast FAQ

Is Genmab stock a buy?

Genmab stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Genmab is a favorable investment for most analysts.

What is Genmab's price target?

Genmab's price target, set by 18 Wall Street analysts, averages $50.6 over the next 12 months. The price target range spans from $40 at the low end to $70 at the high end, suggesting a potential -10.43% change from the previous closing price of $56.49.

How does Genmab stock forecast compare to its benchmarks?

Genmab's stock forecast shows a -10.43% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Genmab over the past three months?

  • October 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 8.33% Strong Buy, 83.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Genmab’s EPS forecast?

Genmab's average annual EPS forecast for its fiscal year ending in December 2024 is $8.66, marking a -87.00% decrease from the reported $66.64 in 2023. Estimates for the following years are $9.62 in 2025, $12.41 in 2026, $17.92 in 2027, and $22.36 in 2028.

What is Genmab’s revenue forecast?

Genmab's average annual revenue forecast for its fiscal year ending in December 2024 is $21.64B, reflecting a 31.37% increase from the reported $16.47B in 2023. The forecast for 2025 is $25.39B, followed by $29.23B for 2026, $33.61B for 2027, and $39.61B for 2028.

What is Genmab’s net income forecast?

Genmab's net income forecast for the fiscal year ending in December 2024 stands at $582.45M, representing a -86.62% decrease from the reported $4.35B in 2023. Projections indicate $708.62M in 2025, $739.7M in 2026, $1.19B in 2027, and $1.47B in 2028.